• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 7

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic Access for Veterans

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

Pα+ Psychedelic Bulletin #195: Psychedelics Namechecked in Trump Cabinet Meeting; Noma Therapy Aims to Disrupt At-Home Ketamine; Christian Angermayer on the Politics and Business...

“Neuropharmacology: Psychedelics on the Brain” – Jim Harris, Rachel Zoeller, DPT, David W. Mcmillan, Ph.D., and Manesh Girn, Ph.D.

GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant...

2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis

The Psychedelic News Feed: September 2, 2024 – December 29, 2024

Psychedelic Drug Development Pipeline Updates (Q1’25)

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart

How Do You Find the Right Facilitator? The Art of Matchmaking...

Pα+ Psychedelic Bulletin #186: As Trump Takes Office, Impact on Psychedelics...

Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes...

Is the DEA Sabotaging Psychedelic Research? Inside the Push to Schedule...

Psychedelics in 2024: From Hype to Hard Realities

1...678...286Page 7 of 286

EDITOR PICKS

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic...

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©